ReviewCurrent neuropharmacology2023
Melatonin as a Chronobiotic with Sleep-promoting Properties.
Review in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Trial
- Trial
- Melatonin in Clinical Practice: Grey Zones Between Chronobiology, Insomnia and Consumer Supplementation.Clocks & sleep · 2026Article
- Time vortex: the circadian-dopaminergic dialogue in Parkinson's disease.NPJ Parkinson's disease · 2026Review
- Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review.Nutrition reviews · 2026Review
- Thermoregulation in Sleep Disorders-Comprehensive Review.Journal of clinical medicine · 2026Review
- Sleep and Rhythmic Profile After Pineal Gland Removal in Humans.Journal of sleep research · 2026Article
- When the biological clock is disordered: circadian rhythm disruption as a core pathophysiological mechanism in anxiety and depression.Frontiers in psychiatry · 2026Review
- Ghrelin's role in sleep and sleep deprivation: a narrative review.Frontiers in psychiatry · 2026Review
- Adolescent circadian sleep health: a review of multimodal assessment strategies and clinical implications.Frontiers in sleep · 2026Review
- Exogenous Melatonin as a Sleep-promoting Agent beyond its Chronobiotic Properties: A Scoping Review of its Effects on Key Sleep-wake Neurotransmitters.Current neuropharmacology · 2026Article
- Redox on the Clock: Sex-Dependent Dynamics of Xanthine Oxidoreductase Isoforms and Melatonin.International journal of molecular sciences · 2025Article
- Melatonin use in the pediatric population: an evolving global concern.World journal of pediatrics : WJP · 2025Review
- Factors associated with sleep duration in a Chinese middle-aged and elderly diabetic population: a cross-sectional study.Acta diabetologica · 2025Article
- Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities.Brain sciences · 2025Article
- Article
- Eat Well, Sleep Well: Exploring the Association Between Eating Behavior and Sleep Quality.Nutrients · 2025Article
- The Cerebral Lymphatic System: Function, Controversies, and Therapeutic Approaches for Central Nervous System Diseases.Cellular and molecular neurobiology · 2025Review
- Unveiling mysteries of aging: the potential of melatonin in preventing neurodegenerative diseases in older adults.Biogerontology · 2025Review
- The impact of melatonin and its agonist on blood pressure and serum endothelin-1 in continuous light and pinealectomized rats.Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of exogenous melatonin (exo-MEL) as a sleep-promoting drug has been under extensive debate due to the lack of consistency of its described effects. In this study, we conduct a systematic and comprehensive review of the literature on the chronobiotic, sleep-inducing, and overall sleep-promoting properties of exo-MEL. To this aim, we first describe the possible pharmacological mechanisms involved in the sleep-promoting properties and then report the corresponding effects of exo-MEL administration on clinical outcomes in: a) healthy subjects, b) circadian rhythm sleep disorders, c) primary insomnia. Timing of administration and doses of exo-MEL received particular attention in this work. The exo-MEL pharmacological effects are hereby interpreted in view of changes in the physiological properties and rhythmicity of endogenous melatonin. Finally, we discuss some translational implications for the personalized use of exo-MEL in the clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.